Glaukos (NYSE:GKOS) CFO Alex Thurman Sells 20,000 Shares

Glaukos Corporation (NYSE:GKOS) CFO Alex Thurman sold 20,000 shares of Glaukos stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $180.13, for a total value of $3,602,600.00. Following the completion of the sale, the chief financial officer owned 43,906 shares in the company, valued at approximately $7,908,787.78. The trade was a 31.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Glaukos Price Performance

Shares of Glaukos stock opened at $182.97 on Wednesday. The business has a 50 day simple moving average of $147.23 and a two-hundred day simple moving average of $128.06. Glaukos Corporation has a 12 month low of $73.16 and a 12 month high of $184.00. The stock has a market capitalization of $10.79 billion, a P/E ratio of -56.30 and a beta of 0.78. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.04 and a quick ratio of 4.46.

Glaukos (NYSE:GKOS) last issued its quarterly earnings results on Wednesday, July 29th. The medical instruments supplier reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.07. Glaukos had a negative return on equity of 6.37% and a negative net margin of 30.68%.The firm had revenue of $185.61 million for the quarter, compared to analyst estimates of $150.93 million. During the same period in the previous year, the company posted ($0.24) earnings per share. The business’s revenue was up 49.6% on a year-over-year basis. As a group, analysts predict that Glaukos Corporation will post -0.35 EPS for the current fiscal year.

Institutional Trading of Glaukos

A number of hedge funds and other institutional investors have recently modified their holdings of GKOS. Wealth Alliance LLC increased its holdings in shares of Glaukos by 4.5% in the 1st quarter. Wealth Alliance LLC now owns 2,297 shares of the medical instruments supplier’s stock valued at $247,000 after acquiring an additional 98 shares during the period. Smartleaf Asset Management LLC boosted its stake in Glaukos by 9.7% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,383 shares of the medical instruments supplier’s stock worth $158,000 after purchasing an additional 122 shares during the period. Larson Financial Group LLC grew its position in Glaukos by 62.0% during the 4th quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier’s stock worth $39,000 after purchasing an additional 132 shares during the last quarter. CWM LLC increased its stake in Glaukos by 25.2% in the fourth quarter. CWM LLC now owns 710 shares of the medical instruments supplier’s stock valued at $80,000 after purchasing an additional 143 shares during the period. Finally, Commonwealth Equity Services LLC increased its stake in Glaukos by 1.7% in the fourth quarter. Commonwealth Equity Services LLC now owns 8,383 shares of the medical instruments supplier’s stock valued at $947,000 after purchasing an additional 144 shares during the period. 99.04% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on GKOS shares. UBS Group started coverage on shares of Glaukos in a report on Tuesday, July 28th. They set a “neutral” rating and a $150.00 target price for the company. Needham & Company LLC boosted their price target on shares of Glaukos from $150.00 to $201.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Glaukos in a research report on Friday, July 17th. William Blair reaffirmed an “outperform” rating on shares of Glaukos in a research note on Tuesday, May 26th. Finally, Wall Street Zen upgraded shares of Glaukos from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. Twelve research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Glaukos presently has an average rating of “Moderate Buy” and a consensus price target of $177.33.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.